| 4.4 -0.16 (-3.51%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.57 | 1-year : | 5.92 |
| Resists | First : | 4.77 | Second : | 5.07 |
| Pivot price | 4.53 |
|||
| Supports | First : | 4.3 | Second : | 3.57 |
| MAs | MA(5) : | 4.5 |
MA(20) : | 4.57 |
| MA(100) : | 4.77 |
MA(250) : | 3.56  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.2 |
D(3) : | 36.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 6.01 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TSHA ] has closed below the lower bollinger band by 6.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TSHA ] is to continue within current trading range. It is unclear right now based on current values. 76% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.63 - 4.65 | 4.65 - 4.67 |
| Low: | 4.29 - 4.31 | 4.31 - 4.33 |
| Close: | 4.37 - 4.4 | 4.4 - 4.43 |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Sat, 21 Mar 2026
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus - simplywall.st
Sat, 21 Mar 2026
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
Sat, 21 Mar 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fri, 20 Mar 2026
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Fri, 20 Mar 2026
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Thu, 19 Mar 2026
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 274 (M) |
| Held by Insiders | 1.7119e+008 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 56,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0098e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 618.5 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 6.31e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -60.13 |
| EBITDA (p.s.) | 5.84259e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 5.94 |
| Dividend | 0 |
| Forward Dividend | 4.896e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|